|
US6924123B2
(en)
*
|
1996-10-29 |
2005-08-02 |
Oxford Biomedica (Uk) Limited |
Lentiviral LTR-deleted vector
|
|
US6319905B1
(en)
|
1998-12-29 |
2001-11-20 |
Cell Genesys, Inc. |
Method of controlling L-Dopa production and of treating dopamine deficiency
|
|
GB0024550D0
(enExample)
|
2000-10-06 |
2000-11-22 |
Oxford Biomedica Ltd |
|
|
US6933377B2
(en)
*
|
2002-07-29 |
2005-08-23 |
Qun Chen |
Compositions comprising multiple immunodeficiency virus subunits for inducing an immune response
|
|
EP1646353A4
(en)
*
|
2003-05-16 |
2008-06-04 |
Acorda Therapeutics Inc |
FUSION PROTEINS FOR THE TREATMENT OF THE CNS
|
|
US20100189727A1
(en)
*
|
2008-12-08 |
2010-07-29 |
Tegopharm Corporation |
Masking Ligands For Reversible Inhibition Of Multivalent Compounds
|
|
WO2012135389A2
(en)
*
|
2011-03-28 |
2012-10-04 |
The Regents Of The University Of California |
Host cells and methods for oxidizing aromatic amino acids
|
|
US10400252B2
(en)
*
|
2011-10-28 |
2019-09-03 |
Oxford Biomedica (Uk) Ltd. |
Catecholamine enzyme fusions
|
|
JP6698114B2
(ja)
*
|
2011-10-28 |
2020-05-27 |
オックスフォード バイオメディカ （ユーケー） リミテッド |
構築物
|
|
GB201118636D0
(en)
*
|
2011-10-28 |
2011-12-07 |
Oxford Biomedica Ltd |
Nucleotide sequence
|
|
DK2956477T4
(da)
|
2013-02-15 |
2024-04-15 |
Bioverativ Therapeutics Inc |
Optimeret faktor viii-gen
|
|
US11008561B2
(en)
|
2014-06-30 |
2021-05-18 |
Bioverativ Therapeutics Inc. |
Optimized factor IX gene
|
|
KR20180118659A
(ko)
|
2016-02-01 |
2018-10-31 |
바이오버라티브 테라퓨틱스 인크. |
최적화된 viii 인자 유전자
|
|
WO2017180587A2
(en)
|
2016-04-11 |
2017-10-19 |
Obsidian Therapeutics, Inc. |
Regulated biocircuit systems
|
|
CN116554320A
(zh)
|
2016-10-12 |
2023-08-08 |
美国比奥维拉迪维股份有限公司 |
抗C1s抗体及其使用方法
|
|
KR102539159B1
(ko)
|
2016-11-07 |
2023-06-02 |
주식회사 뉴라클사이언스 |
서열 유사성을 가진 항-패밀리 19, 멤버 a5 항체 및 그것의 사용 방법
|
|
KR102905526B1
(ko)
|
2017-06-27 |
2025-12-30 |
주식회사 뉴라클사이언스 |
항-fam19a5 항체 및 이의 용도
|
|
KR20220031738A
(ko)
|
2017-06-27 |
2022-03-11 |
주식회사 뉴라클사이언스 |
암 치료를 위한 항-fam19a5 항체의 용도
|
|
EP3645039A4
(en)
|
2017-06-27 |
2021-05-05 |
Neuracle Science Co., Ltd |
USE OF ANTI-FAM19A5 ANTIBODIES TO TREAT FIBROSIS
|
|
EP3645044A4
(en)
|
2017-06-27 |
2021-04-28 |
Neuracle Science Co., Ltd |
USE OF ANTI-FAMILY WITH SEQUENCE SIMILARITY 19, ELEMENT A5 ANTIBODIES TO TREAT GLAUCOMA
|
|
US11192944B2
(en)
|
2017-10-11 |
2021-12-07 |
Bioverativ Usa Inc. |
Methods of inducing complement activity
|
|
SG11202007114VA
(en)
|
2018-02-01 |
2020-08-28 |
Bioverativ Therapeutics Inc |
Use of lentiviral vectors expressing factor viii
|
|
KR20200118913A
(ko)
|
2018-04-24 |
2020-10-16 |
주식회사 뉴라클사이언스 |
신경병성 통증의 치료를 위한 서열 유사성 19, 멤버 a5 항체를 갖는 항-패밀리의 용도
|
|
CA3098805A1
(en)
|
2018-05-10 |
2019-11-14 |
Neuracle Science Co., Ltd. |
Anti-family with sequence similarity 19, member a5 antibodies and method of use thereof
|
|
EP3841124A4
(en)
|
2018-06-29 |
2022-03-23 |
ApitBio, Inc. |
ANTI-L1CAM ANTIBODIES AND USES THEREOF
|
|
EP3867272A4
(en)
|
2018-10-16 |
2022-08-03 |
Neuracle Science Co., Ltd |
USE OF ANTI-FAM19A5 ANTIBODIES
|
|
US20220008515A1
(en)
|
2018-11-16 |
2022-01-13 |
Neoimmunetech, Inc. |
Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor
|
|
AU2019393880A1
(en)
|
2018-12-06 |
2021-07-15 |
Bioverativ Therapeutics Inc. |
Use of lentiviral vectors expressing factor IX
|
|
KR20200071198A
(ko)
|
2018-12-10 |
2020-06-19 |
네오이뮨텍, 인코퍼레이티드 |
Nrf2 발현 조절 기반 T 세포 항암면역치료법
|
|
KR102757347B1
(ko)
|
2018-12-27 |
2025-01-23 |
주식회사 뉴라클사이언스 |
죽상경화증을 치료하기 위한 항-fam19a5 항체의 사용
|
|
CN117964756A
(zh)
|
2019-01-02 |
2024-05-03 |
纽洛可科学有限公司 |
抗序列相似家族19成员a5的抗体及其使用方法
|
|
TW202126284A
(zh)
|
2019-09-30 |
2021-07-16 |
美商百歐維拉提夫治療公司 |
慢病毒載體配製物
|
|
JP2023512456A
(ja)
|
2020-01-13 |
2023-03-27 |
ネオイミューンテック， インコーポレイテッド |
Ｉｌ－７タンパク質と二重特異性抗体の組み合わせで腫瘍を治療する方法
|
|
EP4093752A2
(en)
|
2020-01-22 |
2022-11-30 |
Outpace Bio, Inc. |
Chimeric polypeptides
|
|
EP4093751A1
(en)
|
2020-01-22 |
2022-11-30 |
Outpace Bio, Inc. |
Chimeric polypeptides
|
|
WO2021158783A1
(en)
|
2020-02-05 |
2021-08-12 |
Washington University |
Method of treating a solid tumor with a combination of an il-7 protein and car-bearing immune cells
|
|
WO2021262963A1
(en)
|
2020-06-24 |
2021-12-30 |
Bioverativ Therapeutics Inc. |
Methods for the removal of free factor viii from preparations of lentiviral vectors modified to express said protein
|
|
US20230398216A1
(en)
|
2020-10-22 |
2023-12-14 |
Lyell Immunopharma, Inc. |
Chimeric activation receptors
|
|
US20230398184A1
(en)
|
2020-10-26 |
2023-12-14 |
Neoimmunetech, Inc. |
Methods of inducing stem cell mobilization
|
|
KR20230104176A
(ko)
|
2020-11-02 |
2023-07-07 |
네오이뮨텍, 인코퍼레이티드 |
코로나바이러스의 치료를 위한 인터류킨-7의 용도
|
|
CA3195594A1
(en)
|
2020-11-05 |
2022-05-12 |
Byung Ha Lee |
Method of treating a tumor with a combination of an il-7 protein and a nucleotide vaccine
|
|
WO2022251644A1
(en)
|
2021-05-28 |
2022-12-01 |
Lyell Immunopharma, Inc. |
Nr4a3-deficient immune cells and uses thereof
|
|
WO2022256437A1
(en)
|
2021-06-02 |
2022-12-08 |
Lyell Immunopharma, Inc. |
Nr4a3-deficient immune cells and uses thereof
|
|
EP4408874A1
(en)
|
2021-09-30 |
2024-08-07 |
Bioverativ Therapeutics Inc. |
Nucleic acids encoding factor viii polypeptides with reduced immunogenicity
|
|
WO2023081923A1
(en)
|
2021-11-08 |
2023-05-11 |
Frequency Therapeutics, Inc. |
Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
|
|
CN119836296A
(zh)
|
2021-12-30 |
2025-04-15 |
新免疫技术有限公司 |
用il-7蛋白和vegf拮抗剂的组合治疗肿瘤的方法
|
|
EP4561602A1
(en)
|
2022-07-28 |
2025-06-04 |
Stemcell Technologies Canada Inc. |
Polynucleotides encoding linked antigens and uses thereof
|
|
WO2024102722A1
(en)
|
2022-11-07 |
2024-05-16 |
Neoimmunetech, Inc. |
Methods of treating a tumor with an unmethylated mgmt promoter
|
|
KR20260033048A
(ko)
|
2023-07-03 |
2026-03-10 |
네오이뮨텍, 인코퍼레이티드 |
이종이합체 fc 분자 및 이의 용도
|